Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
HFpEF治療超越SGLT2-Is:GLP-1 RA的添加是否能改善糖尿病患者的心臟代謝風險和結果?
Int J Mol Sci 2022-12-22
Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus.
針對心臟表面脂肪組織:對於合併第2型糖尿病的心臟收縮功能保留不良的心衰,一種潛在的治療策略。
World J Diabetes 2023-09-19
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
鈉葡萄糖共同轉運蛋白2抑制劑在保留射血分數心衰中的益處機制。
Eur Heart J 2023-10-03
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
肥胖、保留射血分數心臟衰竭,以及胰高血糖素樣肽-1 受體激動劑的作用。
ESC Heart Fail 2024-03-29
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.
超越減重:胰高血糖素類治療在心臟代謝性 HFpEF 中新興的角色。
Curr Opin Cardiol 2024-04-04